Definium Therapeutics prices a $700 million public stock offering, according to multiple reports. The company sells shares at $34.00 each, with the offering described as upsized. The proceeds are intended to support the company’s operations and funding needs as it advances its business, though specific allocation details are not provided in the excerpts supplied. One outlet highlights the total offering size of $700 million and the $34.00 share price, while another emphasizes that the offering is upsized and repeats the same per-share pricing. Both accounts frame the transaction as a priced follow-on equity offering, indicating that terms have been finalized for the sale rather than only proposed. No additional information is included in the provided material about underwriters, share count, or expected timing of closing. Overall, the sources agree on the key deal terms: total proceeds of $700 million, an upsized structure, and a $34.00 offering price per share.